- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
DKd vs Kd study design
KYPROLIS®+Darzalex® (daratumumab) and dexamethasone compared to KYPROLIS®+dexamethasone1
CANDOR: Phase 3, randomized, open-label, multicenter study (N = 466) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy1
DKd vs Kd1,2
*For patients > 75 years of age, 20 mg of dexamethasone was administered weekly after the first week, and the entire 20-mg dose was given as a daratumumab pre-infusion medication on days when daratumumab was administered. Dosing of dexamethasone was otherwise split across days when KYPROLIS® was administered in both study arms.1
Inclusion criteria allowed for diverse patient types1-3
Key eligibility criteria (N = 466)
- 1 to 3 prior lines of therapy with ≥PR to ≥ 1 prior therapy
- ECOG PS 0‐2
- CrCl ≥ 20 mL/min
- LVEF ≥ 40%
Key exclusion criteria (N = 466)
- Known moderate or severe persistent asthma within the past 2 years
- Known COPD with a FEV1 < 50% of predicted normal
- Active congestive heart failure (defined as NYHA Class III to IV)
- Symptomatic ischemia
Introducing the phase 3 CANDOR study (DKd vs Kd)

Learn more about the CANDOR study and how DKd may help your patients with relapsed multiple myeloma.
Baseline characteristics, select patient demographics, and prior therapies1,2
DKd (n = 312) | Kd (n = 154) | Total (N = 466) | |
---|---|---|---|
Age – number of patients (%) | |||
18-64 years | 163 (52) | 77 (50) | 240 (52) |
65-74 years | 121 (39) | 55 (36) | 176 (38) |
≥ 75 years | 28 (9) | 22 (14) | 50 (11) |
ECOG PS – number of patients (%) | |||
0 or 1 | 295 (95) | 147 (95) | 442 (95) |
2 | 15 (4.8) | 7 (4.5) | 22 (5) |
Missing | 2 (0.6) | 0 (0.0) | 2 (0.4) |
Cytogenetic risk group determined by FISH – number of patients (%)* | |||
High risk | 48 (15) | 26 (17) | 74 (16) |
Standard risk | 104 (33) | 52 (34) | 156 (33) |
Unknown | 160 (51) | 76 (49) | 236 (51) |
Prior lines of therapy – number of patients (%) | |||
1 | 144 (46) | 70 (45) | 214 (46) |
2 | 99 (32) | 46 (30) | 145 (31) |
3 | 69 (22) | 37 (24) | 106 (23) |
Prior therapy – number of patients (%) | |||
Prior bortezomib | 287 (92) | 134 (87) | 421 (90) |
Prior lenalidomide | 123 (39) | 74 (48) | 197 (42) |
Refractory to lenalidomide† | 99 (32) | 55 (36) | 154 (33) |
Prior ASCT | 195 (62) | 75 (49) | 270 (58) |